Just when we thought the ADHD series was finished, the FDA approved a brand-new ADHD medication.
Centanafadine, FDA approved in the US as Simtriyo, is a once-daily triple reuptake inhibitor that affects dopamine, noradrenaline and serotonin, giving it a mechanism unlike the ADHD medicines we currently use.
In this bonus episode, we look at how centanafadine works, why serotonin is part of the picture, whether it should be considered a stimulant or non-stimulant, what the Phase 3 trials actually showed, and the key safety issues including cardiovascular effects, serotonin syndrome, abuse potential and the paediatric suicidality warning.
We also ask the important question: does a novel mechanism mean a better medication?
And for Australian listeners, we cover what we currently know about TGA approval and whether Simtriyo could eventually become available here.
A concise, clinician-focused update on one of the most interesting new developments in ADHD pharmacotherapy.
Podden och tillhörande omslagsbild på den här sidan tillhör
Kate. Innehållet i podden är skapat av Kate och inte av,
eller tillsammans med, Poddtoppen.
